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Autonomic nerves release ATP, which is processed into adenosine in the synaptic cleft. Adenosine and
ATP exert a negative chronotropic effect in the heart. This study aims to evaluate adenosine and P2
receptors and cellular signalling in cardiac arrest produced by purines in the heart. Right atria of adult
Wistar rats were used to evaluate the effects of adenosine, ATP and CPA (an adenosine A1 receptor
agonist), in the presence and absence of DPCPX, an adenosine A1 receptor antagonist. Effects of ade-
nosine A2 and A3 receptors agonists and antagonists were also investigated. Finally, involvement of
calcium and potassium channels in these responses was assessed using BayK 8644 and 4-Aminopyridine.
Cumulative concentration–effect curves of adenosine and CPA resulted in a negative chronotropic effect
culminating in cardiac arrest at 1000 μM (adenosine) and 1 mM (CPA). Furthermore, ATP produced a
negative chronotropic effect at 1–300 mM and cardiac arrest at 1000 μM in the right atrium. ATPγS (a
non-hydrolysable analogue of ATP) reduced chronotropism only. The effects of adenosine, CPA and ATP
were inhibited by DPCPX, a selective adenosine A1 receptor antagonist. The selective adenosine A2 and A3
receptors antagonists did not alter the chronotropic response of adenosine. 4-Aminopyridine, a blocker
of potassium channels at 10 mM, prevented the cardiac arrest produced by adenosine and ATP, while
BayK 8644, activator of calcium channels, did not prevent cardiac arrest. Adenosine A1 receptor activation
by adenosine and ATP produces cardiac arrest in the right atrium of Wistar rats predominantly through
activation of potassium channels.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Isolated right atria have been used as a bona ﬁde model to study
cardiac chronotropism given the presence in this tissue of the si-
noatrial node (Monfredi et al., 2010), the primary pacemaker of the
heart, which is strictly controlled by the sympathetic and para-
sympathetic nervous systems in vivo (Loffelholz and Pappano, 1985).
Terminal endings of the sympathetic and parasympathetic
nervous systems release ATP as a co-transmitter of noradrenaliney of São Paulo Federal Uni-
ão Paulo, Brazil.
.D. Rodrigues),
.and acetylcholine, respectively. In the synaptic cleft, ATP is con-
verted into adenosine by ectonucleotidases (Vassort, 2001; Zim-
mermann, 2000).
ATP and adenosine modulate cardiac inotropism and chrono-
tropism (Burnstock and Meghji, 1981; Evans et al., 1982) by acti-
vating P2 and adenosine receptors, respectively. Adenosine re-
ceptor activation following ATP administration was also observed
and attributed to the formation of adenosine after ATP hydrolysis
(Moody and Burnstock, 1982). However direct activation of ade-
nosine receptor by ATP in right atria of Wistar rats has not been
directly evaluated.
Four subtypes of adenosine receptors have been identiﬁed and
are ubiquitously expressed in the rat (Dixon et al., 1996). All sub-
types are G-protein-coupled receptors (GPCRs) (Fredholm et al.,
2001). In cardiac muscle and neurons, adenosine A1 receptor
Fig. 1. Role of adenosine A1 receptors in chronotropic effects of adenosine in rat
right atrium. Concentration–effect curve for adenosine (ADO) in right atria in the
absence (control curve) or presence of DPCPX (0.1–10 mM), pre-incubated for
20 min. Adenosine produced cardiac arrest. DPCPX caused a right shift in the curve
of adenosine in a concentration-dependent manner (one-way ANOVA; Po0.05).
Values presented as mean7S.E.M. of 4–8 experiments.
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channels and inhibits calcium channels (Jacobson and Gao, 2006).
Activation of adenosine A2A receptor leads to increase of adenylyl
cyclase activity through preferential activation of Gs protein (Ja-
cobson and Gao, 2006). Adenosine A2B receptors are positively
coupled to adenylyl cyclase and phospholipase C (PLC) (Brackett
and Daly, 1994). When activated, adenosine A3 receptor may lead
to stimulation of PLC (Abbracchio et al., 1995) or inhibition of
adenylyl ciclase (Zhou et al., 1992), both of which result in calcium
mobilisation (Shneyvays et al., 2004).
Although adenosine A1 receptor seems to be the main mediator
of the cardiac effects of adenosine (Ford and Broadley, 1997),
modulation of cardiac activity by all adenosine receptor subtypes
has been shown in different species (Boknik et al., 1997; Salvatore
et al., 1993). Studies suggested that adenosine modulates chron-
otropism in guinea pig right atria through the activation of the
adenosine A3 receptor (Ford and Broadley, 1997). Hove-Madsen
et al. (2006) demonstrated that adenosine A2 receptor activation
modulates the frequency of calcium release from sarcoplasmic
reticulum in human atrium.
In addition to the potential of adenosine to activate multiple
subtypes of receptors in the heart, its downstream signalling
molecules remain elusive, in particular the ion channels that
mediate adenosine receptor responses. Fassina et al. (1991) re-
ported that adenosine A1 receptor activation in guinea pig atrium
leads to signalling through both calcium and potassium channels.
Conversely, Gardner and Broadley (1999) suggested that various
agonists of adenosine A1 receptor may activate both Kþ efﬂux and
calcium channel closure, whereas others may only modulate one
channel.
Therefore, this study was carried out in order to: (a) clarify the
adenosine receptors involved on the effects of adenosine in the
right atrium of Wistar rats; (b) identify the P2 and adenosine re-
ceptors involved in the cardiac arrest produced by ATP and ade-
nosine; (c) verify if the chronotropic effects of ATP are due to its
conversion into adenosine; (d) identify the ion channels involved
in the effects of adenosine and ATP.2. Materials and methods
2.1. Animal and tissue preparation
Animals were handled and maintained in accordance to protocols
approved by the Institutional Research Ethics Committee (protocol
0193/12) at Universidade Federal de São Paulo and following the
animal handling procedures conforming to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals (Council,
2011). Male Wistar rats (Rattus norvegicus), albinus variety, 4–6
months-old, from the institutional animal care facility (INFAR-UNI-
FESP) were killed by decapitation followed by exsanguination under
running water. The rib cage was removed to expose the heart and the
organ was rapidly removed and placed in Krebs–Henseleit solution
(122.3 mM NaCl, 4.6 mM KCl, 1.2 mM KH2PO4, 1.2 mMMgSO4 7H2O,
17.4 mM NaHCO3; 1.5 mM CaCl2H2O, 11.1 mM D-glucose, pH 7.4).
The unpaced right atrium was isolated and suspended in a
10 mL organ bath containing Krebs–Henseleit solution, maintained
at 36.5 °C and aerated with a mixture of 95% O2-5% CO2. Atrium
attachment to organ bath and system speciﬁcations were similar
to that in (Rodrigues et al., 2014).
Tissue was bathed throughout the course of the experiment
with Krebs–Henseleit solution and the resting tension for each
experiment was standardized using the Frank–Starling's mechan-
ism. The optimal tension obtained was 0.8–1.2 mN, which was
used in this study. An equilibration period of 60 min was allowed
before starting the experimental protocols (Mustafa et al., 2009).During the equilibration period tissue was washed every 15 min
with fresh KH solution.
2.2. Drugs
The following compounds: adenosine, N6-Cyclopentyladenosine
(CPA), IB-MECA, CGS21680, ATP (adenosine 5′–triphosphate), αβ-
MeATP, ATPγS, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), 9-Chloro-
2-(2-furanyl)-5-((phenylacetyl)amino)-[1,2,4]triazolo[1,5-c]quinazoline
(MRS 1220), 4-(-2-[7-amino-2-{2-{furyl}{1,2,4}triazolo2,3-a}{1,3,5}
triazin-5-yl amino]ethyl)phenol (ZM 241385), 2–deoxy N6-methyl
adenosine 3,5-diphosphate diammonium salt (MRS2179), 4-Amino-
pyridine and BayK 8644 were purchased from Sigma-Aldrich (St.
Louis, MO, USA). All stock solutions were freshly dissolved in Milli-Q
puriﬁed water, except for adenosine and DPCPX, which were dissolved
in dimethyl sulfoxide. The total volume of dimethyl sulfoxide added
never exceeded 0.2% v v1 of the organ bath.
2.3. Experimental protocol
After the equilibration period, agonist concentration–effect
curves were performed by cumulative dosing at half-log unit
concentration increments. Enough time was allowed for each re-
sponse to reach the plateau before adding a subsequent agonist
concentration. Two concentration–effect curves were constructed
in each right atrium.
To determine the pharmacological reactivity to adenosine
(0.1 nM to 1000 μM), assays were performed in the absence or
presence of three concentrations (0.1, 1 and 10 mM) of DPCPX (a
selective adenosine A1 receptor antagonist), ZM 241385 (a selec-
tive adenosine A2 receptor antagonist) or MRS 1220 (a selective
adenosine A3 receptor antagonist) pre-incubated for 20 min. We
also performed cumulative concentration effect curve with the
selective adenosine A1 receptor agonist, CPA (0.1 nM–3 μM), the
putative adenosine A2 receptor agonist, CGS 21680 (0.1 nM to
1000 μM), and the selective adenosine A3 receptor agonist, IB-
Fig. 2. Role of adenosine A2 and A3 receptors in chronotropic effects of adenosine in rat right atrium. (A) Concentration–effect curves for IB-MECA, selective adenosine A3
receptor agonist. The selective adenosine A3 receptor agonist did not alter atrial chronotropism (Student's t-test, P40.05). (C) Concentration–effect curves for CGS21680,
putative agonist of adenosine A2 and A1 receptors. CGS21680 produced a negative chronotropic effect at 0.3 mM and cardiac arrest at 30 μM. (B and D) Concentration–effect
curves for adenosine (ADO) in the absence (control curve) or presence of MRS1220 (0.1–10 mM), a selective antagonist of adenosine A3 receptors, or ZM 241385 (0.1–10 mM), a
selective antagonist of adenosine A2 receptor, respectively. Pre-incubation of MRS1220 or ZM 241385 did not prevent cardiac arrest produced by adenosine (one-way
ANOVA; P40.05). Values presented as mean7S.E.M. of 5–10 experiments.
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also assessed in the presence of three concentrations (1, 3 and
10 nM) of DPCPX pre-incubated for 60 min.
To determine the pharmacological response of rat right atrium
to ATP (1–1000 μM), a non-cumulative concentration–effect curve
was constructed. Then, the chronotropic regulation of ATP
(100 μM) was tested in the presence of PPADS, Suramin (P2Y re-
ceptor antagonists) or MRS2179 (a selective P2Y1 receptor an-
tagonist), pre-incubated for 20 min. The atrium was also pre-
treated with αβMeATP, a desensitizing P2X agonist, and after
washout and an equilibration period of 45 min ATP was incubated.
We also used ATPγS (100 μM) to distinguish the direct effects of
ATP from its metabolites (e.g. adenosine).
Cardiac arrest of adenosine and ATP (EC100¼1000 μM) was
studied in the presence of the potassium channel blocker 4-ami-
nopyridine (10 mM) or activator of L-type calcium channels BayK
8644 (1–30 μM), pre-incubated for 5 min.2.4. Pharmacological parameters
The pharmacological parameter Emax (maximal effect) refers to
the maximum alteration of chronotropism produced by the full
agonists used in this work. The potency of agonists (pD2), mea-
sured as the negative log of EC50 (Furchgott, 1966), was calculated
to allow comparisons between curves of agonists. The pD2 values
were obtained from GraphPad Instat (GraphPad software, USA).
2.5. Statistical analysis
Individual values are presented as mean7standard error of the
mean (S.E.M.), and at least four experiments (n) were performed in
each case. Mean values were compared using the conventional
analysis of variance for paired samples (Bonferroni post-test) or
were subjected to Student's t-test. Statistical analysis was per-
formed using GraphPad Instat (GraphPad software, USA). The re-
sults were taken to be signiﬁcant if Po0.05.
Fig. 3. Selective adenosine A1 receptor agonist mimic the chronotropic effects of
adenosine in rat right atrium. Concentration–effect curves for CPA in right atria in
the absence (control curve) or presence of DPCPX (1–10 nM), pre-incubated for
60 min. As observed with adenosine, CPA produced a negative chronotropic effect
and cardiac arrest. DPCPX caused a right shift in the curve of CPA in a concentra-
tion-dependent manner (one-way ANOVA; Po0.05). Values presented as
mean7S.E.M. of 4–8 experiments.
Fig. 4. Adenosine receptor agonists potency study. Chronotropic effect of adenosine
receptor agonists in rat right atria. With the exception of IB-MECA, all agonist
caused cardiac arrest (one-way ANOVA; Po0.05). Values presented as mean7S.E.
M. of 4–10 experiments.
Table 1
Pharmacological parameters pD2 and Emax of the adenosine receptor agonists.





a As IB-MECA had no effect, pD2 could not be calculated. CPA
(N6-Cyclopentyladenosine, adenosine A1 receptor agonist); CGS21680 (putative
adenosine A2 receptor agonist); IB-MECA (adenosine A3 receptor agonist)
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3.1. Cardiac arrest in right atria: study of adenosine A1 receptor
Sinoatrial function was studied using the isolated sponta-
neously-beating right atrium preparation.
In this model, adenosine promoted a negative chronotropiceffect with potency (pD2) of 4.4070.16. Moreover, the frequency
of spontaneous contractions (274.6713.8 bpm) was completely
abolished (0 bpm) by adenosine at 1000 μM (Fig. 1).
DPCPX, a selective adenosine A1 receptor antagonist, caused a
concentration-dependent inhibition of the effect of adenosine,
delaying the onset and reducing the intensity of the negative
chronotropic effect at 0.1 mM and 1 mM and preventing cardiac
arrest at 10 mM, being necessary to increase adenosine con-
centration to promote this effect (Po0.05; Fig. 1).
3.2. Study of adenosine A2 and A3 receptors
To rule out the participation of adenosine A2 and A3 receptors,
we used agonists of these receptors and evaluated adenosine ef-
fects in the presence of their selective antagonists. The selective
adenosine A3 receptor agonist, IB-MECA (0.1 nM to 100 mM), had
minimal effect on atrial chronotropism, producing only
4.2771.72% of inhibition at the highest concentration (100 mM;
Fig. 2A).
In addition, MRS 1220 (0.1–10 mM), a selective adenosine A3
receptor antagonist, did not alter the concentration effect curve of
adenosine, and the effect of cardiac arrest was obtained at
1000 μM (Fig. 2B).
Incubation with CGS21680, a putative agonist of the adenosine
A2 receptor (pKi 7.72) and the adenosine A1 receptor (pKi 5.74),
produced a negative chronotropic effect at 0.3 mM and cardiac
arrest at 30 μM (Fig. 2C).
Furthermore, ZM 241385 (0.1–10 mM), a selective adenosine A2
receptor antagonist, did not alter the concentration effect curve of
adenosine or the effect cardiac arrest obtained at 1000 μM
(Fig. 2D).
3.3. Chronotropic effects of CPA, an adenosine A1 receptor agonist
To test if the direct activation of the adenosine A1 receptor
negatively regulates heart rate, we performed a cumulative curve
with N6Cyclopentyladenosine (CPA), an adenosine A1 receptor
agonist. Similarly to adenosine, CPA produced a negative chrono-
tropic effect with a pD2 of 7.5670.07, culminating in cardiac arrest
at 1 mM (Fig. 3).
To conﬁrm the selective action of CPA on adenosine A1 re-
ceptors, we pre-incubated DPCPX in a modiﬁed protocol, reducing
antagonist concentration to 1–10 nM and increasing pre-incuba-
tion period to 60 min. DPCPX also inhibited the effects of CPA in a
concentration-dependent manner (Fig. 3), however with higher
afﬁnity when compared with adenosine assay (Fig. 1).
3.4. Adenosine receptor agonist potency study
The analysis of selective adenosine receptor agonists provides a
rank of potency that is characteristic for each receptor subtype.
The rank of potency observed was CPA4CGS216804ADO»IB-
MECA (Po0.05, Fig. 4). The Emax together with pD2 for each
Fig. 5. Role of P2 receptors in the chronotropic effects of ATP in rat right atrium. (A) Non-cumulative concentration effect curve of ATP (1–1000 μM). ATP produced a
concentration-dependent negative chronotropic effect (1–1000 μM) and cardiac arrest at 1000 μM. (B–E) Chronotropic effects of ATP (100 μM) in the presence of PPADS
(10 μM), suramin (100 μM), P2Y receptor antagonists, MRS2179 (0.3 μM), P2Y1 receptor antagonist, or after treatment of atrium with the P2X receptor desensitizer agonist
αβMeATP (30 μM). Antagonism of P2 receptors did not change the effects of ATP. Values presented as mean7S.E.M. of 4–7 experiments.
Fig. 6. ATP activates adenosine A1 receptor directly in rat right atrium. (A) Negative chronotropic effect of ATP (100 μM) is inhibited by DPCPX (1 μM) (Student's t-test,
Po0,05). (B) Cardiac arrest produced by ATP (1000 μM) is also prevented by DPCPX (1 μM) (Student's t-test, Po0,05). (C) The non-hydrolysable ATP analogue, ATPγS
(100 μM), reduced chronotropism equally to ATP (Student's t-test, P40,05). Values presented as mean7S.E.M. of 4–8 experiments.
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adenosine A1 receptor mediates the adenosine chronotropic ef-
fects in the rat right atria.
3.5. Study of the effects of ATP in the isolated right atria
In rat right atria, ATP (1–1000 mM) produced a negative
chronotropic effect in a concentration-dependent manner. At
1000 mM, ATP also produced cardiac arrest (Fig. 5A).
To identify the receptors involved in the ATP response, we decided
to work with the purine at 100 μM (EC50). Surprisingly, blockade of
P2 receptors with PPADS (10 μM), suramin (100 μM) or the selective
P2Y1 receptor antagonist MRS2179 (100 nM) did not alter Emax of ATP
(Fig. 5B–D). Neither did the pre-treatment of atrium with the de-
sensitizer P2X receptor agonist αβMeATP (30 μM) (Fig. 5E).
As these data indicated that P2 receptors are not responsible
for the effects of ATP, we assessed if activation of adenosine A1
receptor was involved in the reduction of chronotropism produced
by purines. In the presence of DPCPX (1 μM), the negative
chronotropic effect of ATP (100 μM) was practically abolished
(Fig. 6A). Furthermore, DPCPX was able to prevent cardiac arrestproduced by ATP (1000 μM) (Fig. 6B). Since ATP is rapidly de-
graded into adenosine, we assessed the chronotropic effects of
ATPγS, a non-hydrolysable ATP analogue, on the rat right atrium.
ATPγS (100 μM) produced only a negative chronotropic effect,
indistinguishable of ATP (Fig. 6C; P40.05).
3.6. Evaluation of ionic channels participation in adenosine and ATP
cardiac arrest
Next, we evaluated the contribution of calcium and potassium
channels for cardiac arrest produced by adenosine and ATP. Pre-
incubation of right atria with the calcium channel activator BayK
8644 (1 μM) increased atrial chronotropism (Fig. 7A). However,
the presence of BayK 8644 (1–30 μM) did not alter the effect of
adenosine (1000 μM) or ATP (1000 μM) and cardiac arrest was
observed in all the conditions (Fig. 7C).
Pre-incubation with the potassium channel blocker 4-amino-
pyridine increased atrial chronotropism at 3 mM and Emax was
obtained at 10 mM (Fig. 7B). The presence of 4-aminopyridine at
10 mM avoided cardiac arrest produced by adenosine and ATP
(1000 μM; Fig. 7D).
Fig. 7. Evaluation of ion channels involved in cardiac arrest produced by adenosine and ATP. (A and B) Effects of BayK 8644 and 4-aminopiridyne (4AP) on atrial chron-
otropism. BayK 8644 augmented cardiac chronotropism in a concentration-dependent manner up to the higher concentration used (10 μM). 4-Aminopyridine produced an
augmentation of chronotropism at 3 mM, reaching maximum effect at 10 mM. (C and D) Effect of adenosine and ATP (1 mM) on atrial chronotropism of right atria in the
absence and presence of BayK 8644 (10 μM) or 4AP (10 mM). BayK 8644 did not prevent cardiac arrest of adenosine or ATP (C). Conversely, 4AP (10 mM) was able to inhibit
cardiac arrest produced by adenosine or ATP. Values presented as mean7S.E.M. of 4–5 experiments (one-way ANOVA; Po0.05).
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Adenosine and ATP modulate chronotropism in right atria as
previously described by Rockoff and Dobson (1980) and Pelleg
et al. (1990). But the exactly signalling pathways involved in the
cardiac arrest remained unknown. Our study provides strong
evidence that the cardiac arrest induced by adenosine and ATP is
due to activation of potassium channels.
Moreover, the modulation of atrial chronotropism by adenosine
(Fig. 1) suggests the presence of functional adenosine receptors in the
sinoatrial node of Wistar rats. Reduction of cardiac function by ade-
nosine has been described in frogs (Burnstock and Meghji, 1981),
guinea pigs (Meester et al., 1998), humans (Albrecht-Kupper et al.,
2012) and rats (Rockoff and Dobson, 1980). Thus, our results are
consistent with the modulation of cardiac function exerted by purines.
Some studies suggest that adenosine A3 receptor is capable of
reducing the chronotropism in the heart of rodents and humans
(Ford and Broadley, 1997; Headrick and Peart, 2005). In our study,
incubation of the right atria of rats with selective adenosine A3
receptor agonist, IB-MECA, does not alter the chronotropism at the
highest concentration (100 μM). In addition, MRS 1220, a selective
adenosine A3 receptor antagonist, does not block the chronotropiceffect of adenosine. This suggests that in the right atrium of Wistar
rats, adenosine A3 receptor is not functional.
Hove-Madsen et al. (2006) demonstrated that adenosine A2
receptor is functional in human atrial myocytes. Therefore we
evaluated the involvement of adenosine A2 receptor in the reg-
ulation of atrial chronotropism by employing CGS 21680, a puta-
tive agonist of adenosine A2 (pKi 7.72) and A1 receptor (pKi 5.74).
This drug causes a negative chronotropic effect at 1 μM and car-
diac arrest at 30 μM. At this concentration CGS 21680 binds to
both adenosine A2 and A1 receptor (Liang et al., 2010). As we only
noted a decrease of chronotropism, this effect rules out the acti-
vation of adenosine A2 receptor which would lead to an increase of
cardiac frequency. Furthermore, the selective adenosine A2 re-
ceptor antagonist (ZM 241385) does not prevent cardiac arrest
promoted by adenosine. Therefore we attributed the effect of
cardiac arrest produced by CGS 21680 to the selective activation of
the adenosine A1 receptor.
To test the hypothesis that the chronotropic effects of adenosine
were mediated by selective activation of adenosine A1 receptor, we
used CPA, an adenosine A1 receptor agonist. CPA produces negative
chronotropic effects on the right atria of Wistar rats, similar to ade-
nosine. The chronotropic effect and cardiac arrest produced by CPA or
Fig. 8. Schematic model of purinergic system in rat right atria. Adenosine can be obtained by (1) degradation of ATP. Both, adenosine and ATP can activate the adenosine A1
receptor, which cause cardiac arrest by two pathways: (I) a canonical Giα transduction pathway, with consequent inhibition of AC (2), decrease of cAMP levels and calcium
inﬂux (3) and, (II) preferably through opening of potassium channels (4).
H. Camara et al. / European Journal of Pharmacology 768 (2015) 199–206 205adenosine are inhibited by DPCPX, conﬁrming the selective action of
these agonists on the adenosine A1 receptor. Similarly, the activation
of the adenosine A1 receptor by adenosine and stable analogues
produced a negative chronotropic effect on guinea pig right atria
(Ford and Broadley, 1997).
We observed that ATP reduces the chronotropism at con-
centrations higher than 1 mM and produces cardiac arrest at
1000 μM in the right atrium of Wistar rats.
To exclude the possibility that these negative chronotropic ef-
fects were due to processing of ATP to adenosine we used ATPγS, a
non-hydrolysable analogue of ATP. In the right atria, ATPγS in-
duced a negative chronotropic effect only at the maximal con-
centration (100 mM). This result supports the idea that cardiac
arrest produced by ATP is due to direct action of ATP, as observed
in the right atria of guinea pigs (Burnstock and Meghji, 1981;
Moody et al., 1984).
Moreover, we tested the receptor subtype involved in ATP-in-
duced cardiac arrest. P2 receptor antagonists PPADS and Suramin
and even the selective P2Y1 receptor antagonist (MRS2179), which
is the P2Y receptor subtype coupled to Gi, (Filippov et al., 2004;
Marcet et al., 2004) are unable to prevent the cardiac arrest in-
duced by ATP. Also, the cardiac arrest produced by ATP is still
observed after desensitization of P2X receptors by αβMeATP. Only
in the presence of DPCPX the cardiac arrest produced by ATP is
prevented, conﬁrming the selective role of adenosine A1 receptor
in this phenomenon.
Finally, to clarify the cell signalling pathways involved in the
cardiac arrest phenomenon, we used BayK 8644 and 4-aminopyr-
idine, an activator of calcium channels that increases chronotropism
in the right atrium (Borea et al., 1989) and a potassium channel
blocker, respectively. While pre-incubation of right atriumwith BayK
8644 does not prevent cardiac arrest caused by adenosine or ATP,
incubation of 4-aminopyridine completely blocks the effect of the
purines. This result indicates that adenosine and ATP promote car-
diac arrest via the opening of potassium channels. The direct acti-
vation of potassium channels through the βγ subunit after the acti-
vation of Gi proteins appears to be the predominant mechanism of
signal transduction in the atrial tissue of rats as observed in some
studies (Mark and Herlitze, 2000). Furthermore, modulation ofcardiac activity by increasing Kþ conductance has been observed in
the left atrium (Gardner and Broadley, 1999) and in cultured atrial
myocytes of guinea pigs (Belardinelli and Isenberg, 1983), consistent
with our ﬁndings.
Purines and their analogues are widely used to treat cardiac
dysfunctions. For example, adenosine has been clinically used as
an anti-arrhythmic drug (Wilbur and Marchlinski, 1997) and, more
recently, the use of adenosine A1 receptor partial agonists has been
proposed to improve cardiovascular therapy (Albrecht-Kupper
et al., 2012). Therefore, the present study may have clinical impact
because it describes new mechanisms of heart rate control by
signal transduction through the adenosine A1 receptor in the right
atria of a mammalian model. We also suggest that ATP may di-
rectly activate the adenosine receptors, despite the higher afﬁnity
for P2 receptors.5. Conclusion
The ﬁndings of the present study support the conclusion that
adenosine and ATP mediate negative chronotropic effects and
cardiac arrest in the sinoatrial node of Wistar rats due to a selec-
tive activation of the adenosine A1 receptor, which predominantly
leads to the opening of Kþ channels (Fig.8).Funding
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